½ÃÀ庸°í¼­
»óǰÄÚµå
1555653

¼¼°èÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2031³â)

Monkeypox (mpox) Diagnosis Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 179 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Persistence Market Research´Â ÃÖ±Ù ¼¼°è ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ º¸°í¼­¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ÁÖ¿ä ½ÃÀå ¿ªÇп¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» ÅëÇØ ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå ±Ô¸ð(2024E) : 19¾ï 5,000¸¸ ´Þ·¯
  • ½ÃÀå Àü¸ÁÄ¡(2031F) : 24¾ï ´Þ·¯
  • ¼¼°è ½ÃÀå ¼ºÀå·ü(2024-2031³â CAGR) : 4.4%

¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå - Á¶»ç ¹üÀ§

¿¥Å彺 Áø´Ü ½ÃÀå¿¡´Â ¿¥Å彺 ¹ÙÀÌ·¯½ºÀÇ Á¸À縦 °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ Áø´Ü µµ±¸°¡ Æ÷ÇԵ˴ϴÙ. ƯÈ÷ 2022-2023³â »çÀÌ¿¡ ¿¥Æø½º°¡ ´Ù½Ã À¯ÇàÇϸ鼭 Áø´Ü ¼Ö·ç¼ÇÀÇ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. °Ë»ç ¹æ¹ýÀº ½Ç½Ã°£ PCR¿¡¼­ ÇöÀå Áø´Ü ¼Ö·ç¼Ç¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, ÀÌ·¯ÇÑ Áø´Ü µµ±¸´Â º´¿ø, Áø·á¼Ò, ½ÇÇè½Ç ¹× ÀçÅà ȯ°æ¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ºÐÀÚÁø´ÜÀÇ ¹ßÀü, ¼¼°è ÀÎ½Ä Áõ°¡, ±¤¹üÀ§ÇÑ °¨¿°¼º Áúȯ ÆÐ³Î¿¡ ¿ø¼þÀ̵Îâ °Ë»çÀÇ ÅëÇÕÀÔ´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :

¼¼°è ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀåÀº 2022³â ÆÒµ¥¹Í ÀÌÈÄ Àü ¼¼°èÀûÀ¸·Î ³ô¾ÆÁø Àνİú °¨½Ã °­È­ µî ¿©·¯ °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ±â°üÀº Á¶±â ¹ß°ßÀ» ¿ì¼±½ÃÇÏ°í ¹ÙÀÌ·¯½º È®»êÀ» ¾ïÁ¦Çϱâ À§ÇØ Áø´Ü ÀÎÇÁ¶ó¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ PCR ¹× Æ÷ÀÎÆ® ¿Àºê Äɾî(point-of-care) ¼Ö·ç¼Ç°ú °°Àº ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ, ƯÈ÷ Áø´Ü ´É·ÂÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­´Â °Ë»ç°¡ ´õ ½±°í È¿À²ÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø¼þÀ̵Î⠰˻簡 ¸ÖƼÇ÷º½º °¨¿°º´ ÆÐ³Î¿¡ ÅëÇÕµÇ¾î ºü¸£°í ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

¼ö¿ä Áõ°¡¿¡µµ ºÒ±¸ÇÏ°í ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀåÀº ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¸¹Àº Áö¿ª¿¡¼­ ÇÊ¿äÇÑ ÀÇ·á ½Ã¼³°ú ¼÷·ÃµÈ ÀηÂÀÌ ºÎÁ·Çϰí, ½ÅÈï±¹¿¡¼­´Â ÀÎÁöµµ¿Í °Ë»ç ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀ̾ ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ¹× ±ÔÁ¤ Áؼö ¹®Á¦´Â ½ÃÀå ÁøÀÔ À庮À¸·Î ÀÛ¿ëÇÏ¿© »õ·Î¿î Áø´Ü µµ±¸ÀÇ µµÀÔÀÌ Áö¿¬µÇ°í Çõ½ÅÀûÀÎ ±â¼úÀÇ Ã¤ÅÃÀ» Á¦ÇÑÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ƯÈ÷ ÀÇ·á ¿ì¼±¼øÀ§¿Í °ø°ø ÀÇ·á ÀçÁ¤ÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ :

¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀåÀº ƯÈ÷ ÇöÀåÁø´Ü(POCT)ÀÇ È®ÀåÀ» ÅëÇØ Å« ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­´Â ½Å¼ÓÇÏ°í ºÐ»êµÈ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸î ºÐ ¾È¿¡ Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î Áø´Ü ŰƮÀÇ °³¹ßÀº ½ÃÀå¿¡ Çõ½ÅÀÇ ±âȸ¸¦ °¡Á®´Ù ÁÙ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¹ßº´ÀÇ ½Å¼ÓÇÑ ½Äº°°ú ºÀ¼â¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ÀÇ·á ÀÚ¿øÀ» º¸´Ù È¿À²ÀûÀ¸·Î ¹èºÐÇÒ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ¿ø¼þÀ̵Î⠰˻簡 ÀÏ»óÀûÀÎ ÀÇ·á ÇÁ·ÎÅäÄݰú ±¤¹üÀ§ÇÑ °¨¿°¼º Áúȯ ÆÐ³Î¿¡ ÅëÇյǸé ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

  • ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • ±â¼ú ¹ßÀüÀº ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå °æÀï ±¸µµ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?
  • ¼¼°è ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå¿Í ¹Ì·¡ Àü¸ÁÀº?
  • ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡¼­ ¾î¶² Áø´Ü °Ë»ç°¡ äÅÃÀ» ÁÖµµÇϰí Àִ°¡?
  • ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå ±âȸ¸¦ ¾î¶»°Ô Ȱ¿ëÇϰí Àִ°¡?

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • ÁÖ¿ä µ¿Çâ
  • °Å½Ã°æÁ¦ ¿äÀÎ
    • ¼¼°èÀÇ ºÎ¹®º° Àü¸Á
    • ¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ

Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®

  • Áø´Ü Å×½ºÆ® äÅà ºÐ¼®
  • Áúº´ ¿ªÇÐ
  • ±ÔÁ¦ »óȲ
  • ¹ë·ùüÀÎ ºÐ¼®
  • PESTLE ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ ÇÁ·Î¸ð¼Ç Àü·«

Á¦4Àå ¼¼°èÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
    • ½ÃÀå ±Ô¸ð(±Ý¾×)¿Í Àü³â´ëºñ ¼ºÀå·ü
    • Àý´ëÀû ¸ÅÃâ ±âȸ
  • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø
    • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, 2019-2023³â
    • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, 2023-2031³â
  • ¼¼°èÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : Áø´Ü °Ë»ç
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, 2019-2023³â
    • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
      • Ç׿ø ŽÁö °Ë»ç
      • ºÐÀÚ °Ë»ç
    • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áø´Ü °Ë»ç
  • ¼¼°èÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : »ùÇÃ
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, 2019-2023³â
    • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
      • ¼öº¯
      • ÀüÇ÷
      • ÇǺΠº´º¯ Ç¥º»
      • ±âŸ
    • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : »ùÇÃ

Á¦5Àå ¼¼°èÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : Áö¿ª

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, 2019-2023³â
  • ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
    • ºÏ¹Ì
    • À¯·´
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª

Á¦6Àå ºÏ¹ÌÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)

Á¦7Àå À¯·´ÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)

Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)

Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)

Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)

Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¿ø¼þÀ̵Îâ Áø´Ü ½ÃÀå Àü¸Á : °ú°Å(2019-2023) ¹× ¿¹Ãø(2024-2031)

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • ½ÃÀå ±¸Á¶
    • ½ÃÀ庰 °æÀï °­µµ ¸ÅÇÎ
    • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
    • Abbott Molecular, Inc.
    • Laboratory Corporation of America(Labcorp)
    • Cue Health, Inc.
    • Quest Diagnostics Nichols Institute
    • Cepheid
    • DiaCarta, Inc.
    • Roche Molecular Systems, Inc.
    • Meridian Biosciences
    • Vazyme International LLC
    • Siemens Healthcare
    • MedTech Zone
    • Creative Biogene
    • Transasia diagnostics
    • JOYSBIO(Tianjin) Biotechnology Co., Ltd
    • Daan Gene Co., Ltd.
    • BD
    • CERTEST BIOTEC

Á¦13Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
  • µÎÀÚ¾î ¹× ¾à¾î
LSH 24.10.18

Persistence Market Research has recently published an extensive report on the global Monkeypox (Mpox) Diagnosis Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Monkeypox Diagnosis Market Size (2024E): USD 1.95 Bn
  • Projected Market Value (2031F): USD 2.4 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.4%

Monkeypox Diagnosis Market - Report Scope:

The Monkeypox (Mpox) Diagnosis Market encompasses various diagnostic tools used to detect the presence of the monkeypox virus. With the resurgence of monkeypox outbreaks, especially in 2022-2023, diagnostic solutions have gained significant importance. Testing methods range from real-time PCR to point-of-care solutions, and these diagnostic tools are used in hospitals, clinics, laboratories, and home-based settings. The market's growth is driven by advancements in molecular diagnostics, rising global awareness, and the integration of monkeypox testing into broader infectious disease panels.

Market Growth Drivers:

The global Monkeypox Diagnosis Market is driven by multiple key factors, including heightened global awareness and enhanced surveillance following the 2022 outbreak. Governments and healthcare organizations worldwide have prioritized early detection, investing in diagnostic infrastructure to control the spread of the virus. Technological advancements, such as real-time PCR and point-of-care solutions, have made testing more accessible and efficient, especially in regions with limited diagnostic capabilities. Additionally, the integration of monkeypox testing into multiplex infectious disease panels and the growing demand for rapid, accessible solutions are accelerating market growth.

Market Restraints:

Despite the growing demand, the Monkeypox Diagnosis Market faces several challenges. Limited awareness and testing infrastructure in developing regions hinder market expansion, as many areas lack the necessary healthcare facilities and trained personnel. Furthermore, regulatory and compliance challenges create barriers to market entry, delaying the introduction of new diagnostic tools and limiting the adoption of innovative technologies. These factors can impede market growth, particularly in regions where healthcare priorities and public health funding are limited.

Market Opportunities:

The Monkeypox Diagnosis Market offers substantial opportunities, particularly through the expansion of point-of-care testing (POCT). The demand for rapid, decentralized diagnostic solutions is rising, particularly in resource-limited regions. The development of portable, easy-to-use diagnostic kits that deliver accurate results within minutes presents a transformative opportunity for the market. These advancements enable faster identification and containment of outbreaks, providing more efficient healthcare resource allocation. Moreover, the integration of monkeypox testing into routine healthcare protocols and broader infectious disease panels is set to drive future market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Monkeypox (Mpox) Diagnosis Market globally?
  • How are technological advancements influencing the competitive landscape of the Monkeypox Diagnosis Market?
  • What are the emerging trends and future prospects in the global Monkeypox Diagnosis Market?
  • Which diagnostic tests are leading in adoption across various healthcare settings?
  • How are leading players capitalizing on opportunities in the Monkeypox Diagnosis Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Monkeypox Diagnosis Market focus on technological innovations and strategic partnerships to gain a competitive edge. Companies are investing in R&D to develop advanced diagnostic tools, including real-time PCR and point-of-care solutions, to meet the growing demand for rapid, accurate testing. Strategic collaborations with healthcare providers and research institutions enhance market penetration, while direct-to-consumer sales channels, such as e-commerce platforms, improve accessibility. Emphasis on product differentiation, consumer education, and comprehensive marketing strategies fosters market growth and strengthens brand loyalty in the evolving Monkeypox Diagnosis Market landscape.

Key Market Players

  • Abbott Laboratories
  • Aegis Sciences Corporation
  • Applied DNA Sciences, Inc.
  • Becton, Dickinson and Company
  • BioGX
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • CerTest Biotec
  • Creative Biogene
  • Danaher Corporation
  • Flow Health
  • Laboratory Corporation of America Holdings
  • Mayo Clinic Laboratories
  • Quest Diagnostics, Inc.
  • Thermo Fisher Scientific Inc.

Market Segmentation

By Diagnostic Test

  • Antigen Detection Test
  • Molecular Test

By Sample

  • Urine
  • Whole Blood
  • Skin lesion Specimen

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Monkeypox (mpox) Diagnosis Market Snapshot, 2024-2031
  • 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Diagnostic Test Adoption Analysis
  • 3.2. Disease Epidemiology- Monkeypox (mpox)
  • 3.3. Regulatory Landscape
  • 3.4. Value Chain Analysis
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis
  • 3.7. Promotional Strategies, By Key Players

4. Global Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
  • 4.3. Global Monkeypox (mpox) Diagnosis Market Outlook: Diagnostic Test
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
      • 4.3.3.1. Antigen Detection Test
      • 4.3.3.2. Molecular Test
    • 4.3.4. Market Attractiveness Analysis: Diagnostic Test
  • 4.4. Global Monkeypox (mpox) Diagnosis Market Outlook: Sample
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Sample, 2019-2023
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
      • 4.4.3.1. Urine
      • 4.4.3.2. Whole Blood
      • 4.4.3.3. Skin Lesion Specimen
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Sample

5. Global Monkeypox (mpox) Diagnosis Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 6.2.1. By Country
    • 6.2.2. By Diagnostic Test
    • 6.2.3. By Sample
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
    • 6.4.1. Antigen Detection Test
    • 6.4.2. Molecular Test
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
    • 6.5.1. Urine
    • 6.5.2. Whole Blood
    • 6.5.3. Skin Lesion Specimen
    • 6.5.4. Others
  • 6.6. Market Attractiveness Analysis

7. Europe Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 7.2.1. By Country
    • 7.2.2. By Diagnostic Test
    • 7.2.3. By Sample
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
    • 7.4.1. Antigen Detection Test
    • 7.4.2. Molecular Test
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
    • 7.5.1. Urine
    • 7.5.2. Whole Blood
    • 7.5.3. Skin Lesion Specimen
    • 7.5.4. Others
  • 7.6. Market Attractiveness Analysis

8. East Asia Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 8.2.1. By Country
    • 8.2.2. By Diagnostic Test
    • 8.2.3. By Sample
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
    • 8.4.1. Antigen Detection Test
    • 8.4.2. Molecular Test
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
    • 8.5.1. Urine
    • 8.5.2. Whole Blood
    • 8.5.3. Skin Lesion Specimen
    • 8.5.4. Others
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 9.2.1. By Country
    • 9.2.2. By Diagnostic Test
    • 9.2.3. By Sample
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
    • 9.4.1. Antigen Detection Test
    • 9.4.2. Molecular Test
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
    • 9.5.1. Urine
    • 9.5.2. Whole Blood
    • 9.5.3. Skin Lesion Specimen
    • 9.5.4. Others
  • 9.6. Market Attractiveness Analysis

10. Latin America Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 10.2.1. By Country
    • 10.2.2. By Diagnostic Test
    • 10.2.3. By Sample
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
    • 10.4.1. Antigen Detection Test
    • 10.4.2. Molecular Test
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
    • 10.5.1. Urine
    • 10.5.2. Whole Blood
    • 10.5.3. Skin Lesion Specimen
    • 10.5.4. Others
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Monkeypox (mpox) Diagnosis Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 11.2.1. By Country
    • 11.2.2. By Diagnostic Test
    • 11.2.3. By Sample
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2031
    • 11.4.1. Antigen Detection Test
    • 11.4.2. Molecular Test
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2024-2031
    • 11.5.1. Urine
    • 11.5.2. Whole Blood
    • 11.5.3. Skin Lesion Specimen
    • 11.5.4. Others
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping, By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott Molecular, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Laboratory Corporation of America (Labcorp)
    • 12.3.3. Cue Health, Inc.
    • 12.3.4. Quest Diagnostics Nichols Institute
    • 12.3.5. Cepheid
    • 12.3.6. DiaCarta, Inc.
    • 12.3.7. Roche Molecular Systems, Inc.
    • 12.3.8. Meridian Biosciences
    • 12.3.9. Vazyme International LLC
    • 12.3.10. Siemens Healthcare
    • 12.3.11. MedTech Zone
    • 12.3.12. Creative Biogene
    • 12.3.13. Transasia diagnostics
    • 12.3.14. JOYSBIO (Tianjin) Biotechnology Co., Ltd
    • 12.3.15. Daan Gene Co., Ltd.
    • 12.3.16. BD
    • 12.3.17. CERTEST BIOTEC

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦